Intuitive Surgical Inc.
I1SR34.SA
| Exchange: | SA |
| Currency | Brazilian real |
| Fiscal Year End: | December |
| Sector: | Healthcare |
| Industry: | Medical Instruments & Supplies |
| Gic Sector: | Health Care |
| Gic Group: | Health Care Equipment & Services |
| Gic Industry: | Health Care Equipment & Supplies |
| Gic Sub Industry: | Health Care Equipment |
| Home Category: | BDR |
| Is Delisted: | False |
| Description: | Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. It has a collaboration agreement with Fluo Guide A/S for head & neck cancer. The company was incorporated in 1995 and is headquartered in Sunnyvale, California. |
| Address: | 1020 Kifer Road, Sunnyvale, CA, United States, 94086-5304 |
| Website: | https://www.intuitive.com |
| Full Time Employees: | 13676 |
| Updated On: | 2024-11-05 |
Highlights
| Market Capitalization: | 1060990156800 |
| Market Capitalization Mln: | 1060990.15 |
| EBITDA: | 2505100032 |
| PE Ratio: | 80.76 |
| PEG Ratio: | 3.71 |
| Book Value: | 43.74 |
| Earnings Share: | 1.82 |
| Most Recent Quarter: | 2024-06-30 |
| Profit Margin: | 0.28 |
| Operating Margin TTM: | 0.28 |
| Return On Assets TTM: | 0.07 |
| Return On Equity TTM: | 0.15 |
| Revenue TTM: | 7866899968 |
| Revenue Per Share TTM: | 2.22 |
| Quarterly Revenue Growth YOY: | 0.16 |
| Gross Profit TTM: | 4196000000 |
| Diluted Eps TTM: | 1.82 |
| Quarterly Earnings Growth YOY: | 0.34 |
Valuation
| Trailing PE: | 80.76 |
| Forward PE: | 64.51 |
| Price Sales TTM: | 134.86 |
| Price Book MRQ: | 11.44 |
| Enterprise Value: | 1036148380705 |
| Enterprise Value Revenue: | 22.43 |
| Enterprise Value Ebitda: | 69.90 |
Shares
| Shares Outstanding: | 7123590144 |
| Shares Float: | 354056616 |
Technicals
| Beta: | 1.39 |
| 52 Week High: | 149.25 |
| 52 Week Low: | 67.22 |
| 50 Day MA: | 137.12 |
| 200 Day MA: | 114.82 |
Splits & Dividends
| Last Split Factor: | 2:1 |
| Last Split Date: | 2022-11-21 |